Summary & Overview
HCPCS Level II J0883: Argatroban Injection, 1 mg
HCPCS Level II code J0883 denotes a 1 mg injection of argatroban for non-ESRD use, a parenteral direct thrombin inhibitor used as an alternative anticoagulant in select clinical scenarios. Nationally, argatroban claims are important for hospitals and acute care providers managing patients with contraindications to heparin, including suspected heparin-induced thrombocytopenia. Accurate coding of J0883 ensures proper capture of drug utilization and supports clinical documentation for anticoagulation therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of service context and typical sites of care, payer coverage considerations, common modifiers, and where to look for related billing entries. The publication also outlines benchmarking and reimbursement context used by institutions to track utilization and policy updates that may affect coverage for parenteral anticoagulants.
This summary equips billing professionals, revenue cycle leaders, and clinicians with the clinical and billing context for J0883, helping to align documentation with claims submission and payer policy requirements. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0883 describes an injection of argatroban, 1 mg intended for non-end-stage renal disease (non-ESRD) use. This code represents the pharmaceutical drug administration unit for argatroban, a direct thrombin inhibitor used when anticoagulation with heparin is contraindicated or in situations requiring alternative parenteral anticoagulation.
Service Type: Drug administration / Parenteral anticoagulant
Typical Site of Service: Hospital inpatient, hospital outpatient, or other acute care settings where parenteral anticoagulants are administered
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with a confirmed or suspected heparin-induced thrombocytopenia (HIT) requires systemic anticoagulation but cannot receive heparin products. Argatroban, dosed and billed per milligram as J0883 (Injection, argatroban, 1 mg), is administered intravenously in an acute care setting. Typical workflow: a hematology or hospitalist team evaluates platelet trend and HIT laboratory testing (e.g., PF4 antibody, serotonin release assay). After diagnosis or high clinical suspicion, pharmacy prepares argatroban for continuous IV infusion with an initial bolus per protocol as clinically indicated; the drug is titrated to activated partial thromboplastin time (aPTT) targets. Nursing documents infusion start/stop times and any bolus doses; each 1 mg unit used is captured for billing with J0883. Typical sites of service are inpatient acute care hospital units or intensive care units. Common clinical scenarios include: recent cardiac surgery patients with suspected HIT requiring anticoagulation for extracorporeal circuits, patients with venous thromboembolism who develop HIT, and critically ill non-ESRD patients needing parenteral direct thrombin inhibition.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier information reported | Rarely used; default when no specific modifier applies |